Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis
Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis
复制标题
DOI：
10.1093/annonc/mdh008
复制
发表时间：
2004-01-01
影响因子：
50.5
通讯作者：
Nukiwa, T
中科院分区：
文献类型：
--
作者：
Inoue, A;Saijo, Y;Nukiwa, T
背景：本研究的目的是利用药代动力学分析探讨卡铂（CBDCA）和依托泊苷（ETP）联合化疗对接受血液透析（HD）的慢性肾功能衰竭的小细胞肺癌（SCLC）患者的疗效和毒性。患者和方法：三名接受HD的慢性肾功能衰竭的SCLC患者在第1天接受CBDCA（300 mg/m(2)）和ETP（50 mg/m（2））治疗第1天和第3天进行HD，每天完成抗癌药物给药后1小时进行HD。 CBDCA 和 ETP 的药代动力学分析计划至少在每位患者化疗的前两个疗程中进行。结果：三名患者获得了 2 名完全缓解和 1 名部分缓解。两名患者出现 3/4 级中性粒细胞减少症，并因血小板减少症和贫血而需要输血。非血液学毒性为中等。药代动力学分析显示，前24小时血浆中铂和ETP浓度与肾功能正常患者相似，而铂仍保留在血浆中超过90小时。 结论：本研究中使用的CBDCA化疗（第1天300 mg/m(2)）和ETP（第1、3天50 mg/m(2)）可能是接受HD的SCLC患者的合适方案。应注意血液学毒性。
Background: The aim of this study was to use pharmacokinetic analysis to investigate the efficacy and toxicity of combined chemotherapy with carboplatin (CBDCA) and etoposide (ETP) in small-cell lung cancer (SCLC) patients with chronic renal failure undergoing hemodialysis (HD).Patients and methods: Three SCLC patients with chronic renal failure undergoing HD were treated with CBDCA (300 mg/m(2)) on day 1 and ETP (50 mg/m(2)) on days 1 and 3, followed by HD 1 h after completing the administration of anticancer agents on each day. The pharmacokinetic analysis of CBDCA and ETP was planned for at least the first two courses of the chemotherapy in each patient.Results: Two complete responses and one partial response were achieved in the three patients. Two patients experienced grade 3/4 neutropenia and required blood transfusion due to thrombocytopenia and anemia. Non-hematological toxicities were moderate. The pharmacokinetic analysis revealed that the platinum and the ETP concentrations in the plasma were similar to those in patients with normal renal function during the first 24 h, while the platinum still remained in the plasma for over 90 h.Conclusions: Chemotherapy with CBDCA (300 mg/m(2) on day 1) and ETP (50 mg/m(2) on day 1, 3) as used in the present study may be a suitable regimen for SCLC patients undergoing HD, although careful attention should be given to hematological toxicities.